Walleye Capital
BEAM icon

Walleye Capital’s Beam Therapeutics BEAM Stock Holding History

Walleye Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,800
Closed -$355K – 4400
2025
Q4 		$355K Sell
12,800
-45,600
-78% -$1.16M ﹤0.01% 3180
2025
Q3 		$1.42M Buy
58,400
+44,800
+329% +$891K 0.01% 1831
2025
Q2 		$231K Buy
+13,600
New +$237K ﹤0.01% 3244
2024
Q2 		– Sell
-3,200
Closed -$106K – 5591
2024
Q1 		$106K Sell
3,200
-34,100
-91% -$1.06M ﹤0.01% 4368
2023
Q4 		$1.02M Buy
37,300
+15,700
+73% +$390K ﹤0.01% 2331
2023
Q3 		$519K Buy
21,600
+5,300
+33% +$142K ﹤0.01% 2794
2023
Q2 		$520K Buy
16,300
+6,500
+66% +$211K ﹤0.01% 2412
2023
Q1 		$300K Sell
9,800
-10,600
-52% -$418K ﹤0.01% 2123
2022
Q4 		$798K Sell
20,400
-3,000
-13% -$134K 0.01% 1137
2022
Q3 		$1.11M Buy
+23,400
New +$1.33M 0.02% 897

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Walleye Capital's BEAM Position: Q1 2026 in Review

Walleye Capital sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 1,338 shares — an estimated $37.1K sold.

Walleye Capital first reported a position in BEAM in Q3 2021 and held it in 7 quarters. The position peaked at $3.23M in Q1 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Walleye Capital reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,338 Beam Therapeutics shares in Q1 2026, an estimated $37.1K.
  • Walleye Capital first reported a position in Beam Therapeutics in Q3 2021 and held it in 7 quarters.
  • Walleye Capital's Beam Therapeutics position peaked at $3.23M in Q1 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.